Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)

CONCLUSION: Nab-FOLFIRI and Nab-FOLFOX might be hopeful first-line CT options for mPC patients, with promising activity and a good safety profile.PMID:34066784 | PMC:PMC8161763 | DOI:10.3390/curroncol28030164

Source: Current Oncology - June 2, 2021 Category: Cancer & Oncology Authors: Elisa Giommoni Evaristo Maiello Vanja Vaccaro Ermanno Rondini Caterina Vivaldi Giampaolo Tortora Laura Toppo Guido Giordano Tiziana Pia Latiano Cinzia Lamperini Serena Pillozzi Luca Boni Lorenzo Antonuzzo Francesco Di Costanzo Source Type: research